CXO+创新药+AI医疗多点开花！这个ETF在港股医药赛道份额增速第一

Group 1 - The Hang Seng Biotechnology Index has seen a year-to-date increase of nearly 14%, leading key indices in the Hong Kong stock market, highlighting its high elasticity characteristics [1] - As of January 9, the Hang Seng Pharmaceutical ETF (159892) has attracted over 800 million in capital subscriptions this year, with a share growth exceeding 13%, ranking first in the Hong Kong pharmaceutical and healthcare sector [1] - The Hang Seng Biotechnology Index, launched by the Hang Seng Index Company in 2019, reflects the overall performance of the biotechnology sector in the Hong Kong stock market, capturing the performance of the entire innovation drug industry chain by also considering upstream CXO and AI medical sectors [1] Group 2 - The internationalization capabilities of pharmaceutical companies and supportive industrial policies have led to an increase in the market sentiment and risk appetite for innovative drugs, with widespread consensus on the global competitiveness of Chinese innovative drug assets [1] - The CXO sector is benefiting from the onset of a rate-cutting cycle and domestic innovation-driven growth, indicating a potential turning point in the larger cycle; the Federal Reserve's rate cuts are expected to bring liquidity easing, which may improve the secondary market for domestic innovative drugs and lead to a recovery in primary market financing, while overseas demand recovery is likely to enhance CXO demand and performance [1]